12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Invokana canagliflozin regulatory update

Last June, J&J submitted an MAA to EMA for canagliflozin. J&J has worldwide rights to Invokana except in some parts of Asia from Mitsubishi Tanabe.

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J....

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >